However, the results are inconsistent for heterozygotic carriers (Farrer et al., 1997), with some studies suggesting that APOE ε4 may have less predictive impact on AD outcomes in African-ancestry populations, including African Americans (Rajabli et al., 2018). This evidence concerns the gene APOE and Alzheimer disease.